Normoson en es it fr

Normoson Brand names, Normoson Analogs

Normoson Brand Names Mixture

  • No information avaliable

Normoson Chemical_Formula

C2H8O7P2

Normoson RX_link

http://www.rxlist.com/cgi/generic2/didronel.htm

Normoson fda sheet

Normoson FDA

Normoson msds (material safety sheet)

Normoson MSDS

Normoson Synthesis Reference

No information avaliable

Normoson Molecular Weight

206.028 g/mol

Normoson Melting Point

No information avaliable

Normoson H2O Solubility

No information avaliable

Normoson State

Solid

Normoson LogP

-2.734

Normoson Dosage Forms

Solution for injection (50mg/mL); Tablet (200, 400 mg)

Normoson Indication

For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

Normoson Pharmacology

Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Normoson Absorption

The amount of drug absorbed after an oral dose is approximately 3%.

Normoson side effects and Toxicity

Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

Normoson Patient Information

Normoson Organisms Affected

Humans and other mammals